Biosyngen receives FDA approval to start Phase I trial for TCR therapy
The US FDA has awarded Biosyngen’s IND for the T-cell receptor therapy, BRL03, to start Phase I/II trials in lung and other solid cancers.
The US FDA has awarded Biosyngen’s IND for the T-cell receptor therapy, BRL03, to start Phase I/II trials in lung and other solid cancers.
What's Your Reaction?
